Solid Tumors clinical trials

Explore recruiting solid tumors clinical trials.

Recruiting solid tumors studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Solid Tumors trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

An Open-label, Phase I/II Multicenter Clinical Trial of NECVAX-NEO1 in Addition to Anti-PD-1 or Anti-PD-L1 Monoclonal Antibody Therapy in Patients with Solid Tumors (NECVAX-NEO1-02-INT).

Lithuania, Germany, Spain

Phase I and Phase II (Integrated)- Other EU CTIS Study details

A first in human Phase 1/2 open-label, multicenter, dose escalation and expansion study of PRS-344/S095012 in patients with solid tumors.

Spain, France, Belgium

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

C5721002 _ A Randomized, Open-Label, Phase 3 Trial of Tisotumab Vedotin vs Investigator’s Choice Chemotherapy in Second- or Third-Line Recurrent or Metastatic Cervical Cancer

Sweden, Czechia, Finland, Netherlands, Hungary, Norway +7 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 1b Trial of ARV-471 in Combination with Everolimus in Patients with ER+, HER2– Advanced or Metastatic Breast Cancer

Spain

Human Pharmacology (Phase I)- Other EU CTIS Study details

A Phase 1b/2 Study to Evaluate the Efficacy and Safety of Investigational Agents as Monotherapy or in Combination With Pembrolizumab for the Treatment of Participants With PD-1/L1-refractory Extensive-Stage Small Cell Lung Cancer in Need of Second-Line Therapy (KEYNOTE-B98)

Spain, Hungary, Poland, Austria, Italy

Phase I and Phase II (Integrated)- Other EU CTIS Study details

A Phase 3, Randomized, Placebo-controlled, Double-blind Study of Vimseltinib to Assess the Efficacy and Safety in Patients with Tenosynovial Giant Cell Tumor (MOTION)

Germany, Netherlands, France, Spain, Italy, Norway +1 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Solid Tumors trials by city

Solid Tumors in Toronto Solid Tumors in Vancouver Solid Tumors in Montreal Solid Tumors in Calgary Solid Tumors in Edmonton Solid Tumors in Ottawa Solid Tumors in Winnipeg Solid Tumors in Quebec City Solid Tumors in Hamilton Solid Tumors in Kitchener Solid Tumors in London Solid Tumors in Halifax Solid Tumors in New York Solid Tumors in Los Angeles Solid Tumors in Chicago Solid Tumors in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease